Summary of Hubei Meirya Co., Ltd. Annual Shareholders Meeting Core Viewpoint The company is preparing for its 2024 Annual Shareholders Meeting, focusing on governance, operational performance, and future strategies amidst a challenging economic environment. Group 1: Meeting Procedures and Governance - The meeting will ensure the legal rights of all shareholders and maintain order and efficiency [3][5] - Shareholders must register and confirm their attendance before the meeting starts [4][5] - The meeting will follow a structured agenda, allowing shareholders to express their opinions and vote on resolutions [4][6] Group 2: Operational Performance and Financial Overview - The company reported a total asset decrease of 16.52% from 2023, with total assets at 105,079.28 million yuan [17] - The company’s revenue for 2024 was 32,950.20 million yuan, a decrease of 27.42% compared to 2023 [18] - The net profit attributable to shareholders was -68,103,594.71 yuan, indicating a challenging financial year [21] Group 3: Future Development Strategies - The company aims to enhance brand building and industrial transformation, focusing on quality, technology, and brand strength [12] - Plans include improving market competitiveness and expanding customer outreach while maintaining operational efficiency [12][13] - The company will not distribute profits for 2024 due to negative net profit, prioritizing liquidity and risk management [21] Group 4: Audit and Compliance - The company has engaged Zhongshen Zhonghuan CPA as its auditing firm for 2025, which has a strong track record in the industry [22][23] - The audit firm has not faced significant legal issues in recent years, ensuring reliability in financial reporting [23]

目 录 大参林医药集团股份有限公司 会议材料 二○二五年六月 大参林医药集团股份有限公司 会议表决方式：现场投票与网络投票相结合的方式 会议时间：2025 年 6 月 25 日上午 10 点 30 分 网络投票：2025 年 6 月 25 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30， 会议地点：广东省广州市荔湾区龙溪大道 410 号大参林医药集团股份有限公 司综合楼 4 楼会议室 出席人员：公司股东、董事、监事、董事会秘书 列席人员：高级管理人员、律师 主持人：董事长柯云峰先生 见证律师：北京市金杜（广州）律师事务所律师 会议安排： 一、 参会人签到 二、 主持人宣布会议开始 三、 主持人宣读本次会议出席的股东人数及其代表的股份数 四、 推选监票人、计票人 五、 宣读会议须知 六、 董事会秘书宣读各议案并审议表决 序号 议案名称 非累积投票议案 七、 股东发言 八、 股东投票，由主持人宣布投票表决结束 九、 休会；监票人、计票人统计表决票 十、 监票人宣读表决结果 十一、 公司董事会秘书宣读 ...

Core Viewpoint - Multiple securities firms, including Dongfang Securities, Zheshang Securities, and CITIC Securities, have issued positive ratings for Dazhenglin (603233.SH), highlighting its performance in 2024 and Q1 2025, business layout, and future prospects [1][2]. Group 1: Financial Performance - In 2024, Dazhenglin achieved a revenue of 26.497 billion yuan, representing a year-on-year growth of 8.01%, with a net profit attributable to shareholders of 915 million yuan [1]. - For Q1 2025, the company reported a revenue of 6.956 billion yuan, a year-on-year increase of 3.02%, and a net profit of 460 million yuan, reflecting a significant year-on-year growth of 15.45% and a remarkable quarter-on-quarter surge of 712.26% [1]. Group 2: Business Expansion and Network - As of March 2025, Dazhenglin operates a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct-operated stores, covering 21 provinces across the country [2]. - The company plans to focus on optimizing its store network and accelerating franchise development in 2025, aiming to enhance market share and brand influence in underrepresented areas [2]. Group 3: Digital Transformation and New Retail - Dazhenglin is advancing its new retail channels and digital initiatives, with over 110 million private domain members and nearly 60 million active members as of the end of 2024 [3]. - The company has implemented an O2O delivery service with an 80.38% store coverage rate and is enhancing its online and offline integration through a "central warehouse + provincial warehouse + regional warehouse + store" model [3]. - The introduction of AI technology, such as "AI Xiaosan," aims to improve operational efficiency by providing accurate instant responses and intelligent analysis [3].

证券代码：603233 证券简称：大参林 公告编号：2025-039 大参林医药集团股份有限公司 关于聘请战略顾问暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 根据公司战略发展、产业布局的需要，大参林医药集团股份有限公司（以下简称"公司"） 拟聘请柯康 保先生为公司战略顾问，为公司总体发展目标、发展战略、经营战略等活动提供顾问服务，并拟与柯康 保先生签订《战略顾问协议》，聘期三年，每年薪酬为人民币120万元（含税）。 ● 柯康保先生为公司控股股东及实际控制人之一，本次聘请行为构成关联交易，但不构成重大资产重 组，本次聘请事宜的实施不存在重大法律障碍。 ● 根据《上海证券交易所股票上市规则》的规定，本次关联交易事项在公司董事会的审批权限内，无需 提交公司股东大会审议。 一、关联交易概述 1、关联关系说明 柯康保先生为公司控股股东及实际控制人之一、持有公司5%以上股份的股东，根据《上海证券交易所 股票上市规则》的相关规定，柯康保先生为公司的关联自然人，公司与其签订的《战略顾问协议》构成 关联 ...

Core Viewpoint - The strategic collaboration between Yaoshi Bang and Yujian focuses on the application of collaborative robots and AI products in the pharmaceutical sector, aiming to enhance the integration of robotics and the pharmaceutical industry [1] Group 1: Company Performance - Yaoshi Bang's stock price has surged, achieving a 52% increase in May and over 120% year-to-date, with a market capitalization exceeding HKD 7.5 billion [1][4] - The company reported a revenue of CNY 17.904 billion for 2024, a year-on-year increase of 5.5%, and a net profit of CNY 157 million, marking a 20.1% increase [3] - The company has successfully transitioned to profitability, indicating that previous investments in digitalization and supply chain optimization are yielding results [3] Group 2: Market Trends - The pharmaceutical sector in Hong Kong has shown strong performance, with the Hong Kong and A-share pharmaceutical indices rising over 35% and 43% respectively in 2025 [2] - The A-share pharmaceutical and biotechnology sector has also rebounded significantly, with a single-day trading volume of CNY 127.9 billion on June 3 [2] Group 3: Strategic Initiatives - Yaoshi Bang has initiated a share repurchase plan worth CNY 100 million, having repurchased 5.275 million shares for nearly HKD 40 million [4] - The company is entering the pharmaceutical robotics and AI model sector, collaborating with Yujian Technology to explore high-value business opportunities in retail pharmacies [3] Group 4: Analyst Perspectives - Analysts from Changcheng Securities project that Yaoshi Bang's revenue will reach CNY 20.327 billion, CNY 23.375 billion, and CNY 27.120 billion from 2025 to 2027, with corresponding net profits of CNY 124 million, CNY 379 million, and CNY 720 million [6] - Tianfeng Securities highlights that the company is entering a new phase of sustained profitability, marking a significant milestone in its growth trajectory [6] - Xinda Securities notes that the company has completed its major capital expenditure phase and is now positioned to enhance profitability through high-margin business initiatives [6]

一年关店118家的连锁药房巨头漱玉平民再度遭遇医保解约。近日，山东省医疗保障局的一纸公告显 示，济南两家漱玉平民药房被正式解除省直医保协议关系。 就在消息公布的前三天，漱玉平民大药房连锁股份有限公司（简称"漱玉平民"）创始人兼总裁秦光霞宣 布减持公司3%股份，套现约1.5亿元。这位与董事长李文杰并肩创业26年的元老，在公司遭遇上市首次 年度亏损之后选择减持，引发市场一片哗然。 就在漱玉平民遭遇上市以来首次年度亏损和医保频频解约的敏感时刻，创始人却选择高位套现，这家曾 经风光上市的医药零售巨头如今"屋漏偏逢连夜雨"，正面临着前所未有的生存和信任危机。 医保违规"常客" 漱玉平民作为一家知名连锁药房，在济南、青岛等地区拥有众多门店，此次山东省医保局解除协议的两 家漱玉平民门店未公布具体事由，对此记者致电漱玉平民，对方工作人员表示"不了解详情"。而记者致 电山东省医疗保障局被告知："如果自动选择解除医保协议的话会在通告中体现，如未标明则可能有不 便告知的原因。" "解除医保协议的原因主要可分为两类，一种是医保部门主动解除，一种是药店主动申请解除。如果是 医保部门主动解除原因可能为医保违规或重大信息变更未报备。"医药 ...

一心堂药业集团股份有限公司 投资者交流活动会议记录 时间：2025 年 6 月 4 日 14:00-15:00 地点：一心堂药业集团股份有限公司总部 召开方式：现场交流 投资者：中泰证券 祝嘉琦 孙宇瑶、中信证券 张斌斌 魏通、国海证 券 年庆功、招商信诺 詹孝颖、广发证券 李桠桐、国信自营 曹嘉诚、 摩根基金 蔡云翔等投资者共 23 人。 接待人：董事郭春丽女士、集团非药品事业部非药推广部总监刘骏先 生、云南公司副总经理谢建兵先生、证券事务代表阴贯香女士。 一心堂药业集团股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日（星 期三）下午 14:00-15:00 在公司总部进行投资者现场交流活动，公司管理层就投 资者关心的问题进行交流，内容如下： 问题一：存量门店选址是针对药品销售来开展的吗？转型门店选址的依据是什 么？ 答：存量门店选址是依据各个区域目标人群来展开，目前改造门店主要是针 对存量的门店的改造，从存量门店中拿出一部分适合的门店进行改造。如开展谷 子类产品业务并不适合所有门店，我们会挑选部分门店进行改造，并开展此类业 务。 问题二：调改门店的非药占比是多少？会不会影响药品类的销量？ ...

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 编号：TG202506-001 | | □特定对象调研 □分析师会议 | | | | | --- | --- | --- | --- | --- | | | □媒体采访 业绩说明会 | | | | | 投资者关系活动类别 | □新闻发布会 路演活动 | | | | | | ☑现场参观 | | | | | | □其他（电话会议） | | | | | 参与单位名称及人员 | 中泰证券 祝嘉琦 孙宇瑶、中信证券 张斌斌 魏通、国海 | | | | | | 证券 年庆功、招商信诺 詹孝颖、广发证券 李桠桐、国信 | | | | | 姓名 | 自营 曹嘉诚、摩根基金 蔡云翔等投资者共 23 人。 | | | | | 时间 | 2025 6 4 14:00-15:00 | 年 | 月 | 日 | | 地点 | 一心堂药业集团股份有限公司总部 | | | | | | 董事郭春丽女士、集团非药品事业部非药推广部总监刘骏 | | | | | 公司接待人员姓名 | 先生、云南公司副总经理谢建兵先生、证券事务代表阴贯 ...

Core Insights - Dingdang Health is intensifying its efforts in the pharmaceutical new retail sector by launching a 15-minute urgent medication delivery service and signing agreements with multiple pharmaceutical companies to advance the "Original Drug Supply Alliance" project [1][2] Group 1: Company Developments - Dingdang Kuaiyao has achieved a cumulative delivery of 123 million orders at night over the past ten years, evolving from a single medication retail platform to a comprehensive health management platform that includes online health consultations, medication guidance, and post-diagnosis health management [2] - The company has introduced a multi-functional smart solution called the A-LL dual-wheel drive growth model, focusing on enhancing brand influence for pharmaceutical companies and expanding its pharmacy network in key regions such as Beijing, Tianjin, Shanghai, Hangzhou, Guangzhou, and Shenzhen [2] Group 2: Market Trends - The demand for immediate medication retail is increasing due to changing consumer habits and a heightened focus on health consumption, particularly among severe patients, children, and the elderly, who view original drugs as essential for quality living [1] - The deepening impact of centralized procurement policies has led to some original drugs exiting hospital channels, prompting patients to turn to online pharmaceutical platforms for their needs [1] Group 3: Policy Support - Continuous policy support is a significant backdrop for Dingdang Health's push into pharmaceutical new retail, with the Ministry of Commerce and the National Health Commission promoting health consumption and the integration of medical services into retail pharmacy operations [3] - The 2025 action plan emphasizes the role of retail pharmacies in health promotion and encourages the adoption of innovative "Internet+" medical service models, enhancing the flow of electronic prescriptions and improving convenient medical service demands [3]

Core Viewpoint - Two Hong Kong companies, Yuejiang (02432.HK) and Yaoshibang (09885.HK), have signed a strategic cooperation agreement to explore the application of intelligent robotics and AI in the pharmaceutical industry, aiming to enhance efficiency and innovation across the entire supply chain [1][2]. Group 1: Strategic Cooperation - The partnership will focus on the development and deployment of intelligent robots in pharmacies and drug warehouses, with both companies sharing technology and intellectual property generated during the collaboration [2]. - Yuejiang will handle technology development, production, and maintenance of the robots, while Yaoshibang will focus on application research and sales [1][2]. Group 2: Market Potential - According to a report by ZhiShi Industry Consulting, the global collaborative robot market in the healthcare sector is expected to reach $373 million by 2028, indicating significant growth potential [3]. - Yuejiang anticipates that the pharmaceutical sector will become a key area for the application and promotion of collaborative robots [3]. Group 3: Company Performance - On June 3, Yuejiang's stock rose by 0.87%, with a market capitalization exceeding HKD 20 billion, reflecting a year-to-date increase of 144.30% [3]. - Yaoshibang's stock increased by 4.79% on the same day, with a market capitalization of approximately HKD 6.9 billion and a year-to-date rise of 78.37% [3].